- Home
- EARN vs FENC Comparison
EARN vs FENC Comparison
Compare EARN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EARN | FENC |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 230.8M |
| IPO Year | 2012 | 2010 |
Fundamental Metrics
Financial Performance| Metric | EARN | FENC |
|---|---|---|
| Price | $4.37 | $10.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.38 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 365.7K | 254.7K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $7.69 | $65.12 |
| Revenue Next Year | $19.57 | $41.08 |
| P/E Ratio | ★ N/A | $1,070.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.27 | $5.65 |
| 52 Week High | $6.08 | $11.31 |
Technical Indicators
Market Signals| Indicator | EARN | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 65.34 |
| Support Level | $4.31 | $7.40 |
| Resistance Level | $4.78 | N/A |
| Average True Range (ATR) | 0.10 | 0.52 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 5.71 | 75.40 |
Price Performance
Historical ComparisonAbout EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.